Skip to main content
. 2018 Jul 17;6:97. doi: 10.3389/fbioe.2018.00097

Figure 1.

Figure 1

Activity and toxicity of Dasatinib and Erdafitinib. (A,B) Intracellular detection of total and phospho-SRC in SW620 (A) and HCT116 (B) show that Dasatinib inhibits SRC phosphorylation. (C) Western blot analysis confirms that Dasatinib suppresses SRC phosphorylation in cancer cells. (D) Growth curve of SW620 and HCT116 over 48 h in presence or absence of the described drugs at the described concentration. In red the in vitro used concentration for the two drugs. (E) Quantification of cell dead by flow cytometry after 7 days in 3D assay conditions. (F) Viability measurements of the different cell lines cultured in 2D conditions in the presence or absence of the corresponding inhibitor for 48 h using DAPI staining.